<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">279568</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Opyt primeneniya trastuzumaba v respublike Bashkortostan</article-title><trans-title-group xml:lang="ru"><trans-title>Опыт применения трастузумаба в республике Башкортостан</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sakaeva</surname><given-names>D. D</given-names></name><name xml:lang="ru"><surname>Сакаева</surname><given-names>Д. Д</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, заместитель главврача по химиотерапии</p></bio><email>d_sakaeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kunafina</surname><given-names>R. I</given-names></name><name xml:lang="ru"><surname>Кунафина</surname><given-names>Р. И</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач кабинета химиотерапии</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Popova</surname><given-names>E. V</given-names></name><name xml:lang="ru"><surname>Попова</surname><given-names>Е. В</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач кабинета химиотерапии</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГБУЗ РКОД МЗ РБ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-04-20" publication-format="electronic"><day>20</day><month>04</month><year>2012</year></pub-date><volume>19</volume><issue>8</issue><issue-title xml:lang="en">NO8 (2012)</issue-title><issue-title xml:lang="ru">№8 (2012)</issue-title><fpage>74</fpage><lpage>76</lpage><history><date date-type="received" iso-8601-date="2023-02-24"><day>24</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, ООО «Бионика Медиа»</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/279568">https://journals.eco-vector.com/2073-4034/article/view/279568</self-uri><abstract xml:lang="en"><p>This article discusses the practice of treatment of breast cancer with HER2/neu overexpression in the Republic of Bashkortostan. Trastuzumab was used as the drug that significantly improves the results of therapy. Patients were divided into two groups. In the study group, the drug was administered in adjuvant mode after the surgery, chemotherapy and radiation therapy. Times of recurrence and metastasis were analyzed in both groups. The use of trastuzumab in complex therapy allows to individualize the therapy for breast cancer and improve treatment outcomes.</p></abstract><trans-abstract xml:lang="ru"><p>В статье рассматривается практика лечения рака молочной железы с гиперэкспрессией HER2/neu в Республике Башкортостан. В качестве препарата, значительно улучшающего результаты терапии, использовали трастузумаб. Для исследования было сформировано две группы пациенток. Препарат назначали в адъвантном режиме после проведения оперативного лечения, химиотерапии и лучевой терапии в основной группе. Были проанализированы сроки развития рецидивов, метастазирования в обеих группах. Применение трастузумаба в комплексной терапии позволяет индивидуализировать терапию рака молочной железы и улучшать результаты лечения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>HER2/neu overexpression</kwd><kwd>trastuzumab</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>гиперэкспрессия HER2/neu</kwd><kwd>трастузумаб</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Данные ежегодного отчета ГУЗ РКОД РБ.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2neu oncogene. Science 1987;235: 177-82.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Harari D, Yarden Y. Molecular mechanism underlaying ErbB/HER2 action in breast cancer. Oncogene 2000;19:6102-14.</mixed-citation></ref></ref-list></back></article>
